IP Library Granted Patent US 9,145,365
Granted Patent B2
US 9,145,365 · App. 14/273,270 · Granted Sep 29, 2015

Process for the preparation of Roflumilast

Inventors: Priyesh Vijaykar (Hyderabad, IN); Dattatrey Kokane (Hyderabad, IN); Sushant Gharat (Hyderabad, IN); Dhananjay Shinde (Hyderabad, IN); Manojkumar Bindu (Hyderabad, IN); Vinayak Gore (Hyderabad, IN)
Assignee: Mylan Laboratories Ltd.
C07D213/75C07C45/64C07C51/29C07C2101/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,145,365
App. No.
14/273,270
Granted
Sep 29, 2015
Kind
B2
Abstract

The present invention relates to an improved process for the preparation of Roflumilast. The present invention also relates to crystalline Form-I of Roflumilast.

Claims (14)

1. A process for the preparation of Roflumilast comprising the steps of:

a) reacting 4-Difluoromethoxy-3-hydroxy benzaldehyde of Formula II with a cyclopropylmethyl compound of Formula III in the presence of an organic base to obtain 3-cyclopropylmethoxy-4-Difluoromethoxy benzaldehyde of Formula IV

wherein X is a leaving group,

b) oxidising the obtained aldehyde compound of Formula IV into 3-cyclopropylmethoxy-4-Difluoromethoxy benzoic acid of Formula V,

c) converting 3-cyclopropylmethoxy-4-Difluoromethoxy benzoic acid of Formula V to its acid halide and condensing with 4-amino 3,5-Dichloropyridine in the presence of base to obtain Roflumilast, and

d) optionally purifying Roflumilast in an organic solvent to get pure Roflumilast.

2. The process according to claim 1 , wherein the organic base used in the step-a is 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU).

3. The process according to claim 1 , wherein the leaving group in step-a is selected from the group consisting of a halogen, alkylsulfonyloxy, and arylsulfonyloxy.

4. The process according to claim 1 , wherein the oxidation in step-b is carried out in the presence of sulfamic acid and sodium chlorite.

5. The process according to claim 1 , wherein the base used in the step-c is selected from the group consisting of alkali metal hydrides and alkali metal carbonates.

6. The process according to claim 5 , wherein the base is selected from the group consisting of sodium hydride and potassium hydride.

7. The process according to claim 1 , wherein the acid halide in step-c is produced using a halogenating agent and wherein the halogenating agent is thionyl chloride.

8. The process according to claim 1 , wherein the organic solvent used in step-d for the purification of Roflumilast is selected from alcoholic solvents.

9. The process according to claim 8 , wherein the alcoholic solvent is selected from the group consisting of methanol, ethanol, isopropanol, and mixtures thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MYLAN LABORATORIES LIMITED
To: TIANISH LABORATORIES PRIVATE LIMITED
Reel/Frame 068861/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2014
From: VIJAYKAR, PRIYESH; KOKANE, DATTATREY; GHARAT, SUSHANT; SHINDE, DHANANJAY; BINDU, MANOJKUMAR; GORE, VINAYAK
To: MYLAN LABORATORIES LTD.
Reel/Frame 032853/0455 →
Priority Claims (1)
IN 3840/CHE/2011 · Nov 9, 2011 · national
Continuity (2)
Continuation PCTIN2012000738 · Nov 8, 2012
Related Publication 20140275551A1 · Sep 18, 2014